Waqaas Al-Siddiq, Chairman, CEO and Founder of Biotricity (OTCMKTS:BTCY) explains the investment highlights of his company in an exclusive interview with the Wall Street Transcript.
QUOTE:
“Mr. Al-Siddiq: It is a lower-cost alternative to monitoring someone in the hospital, but a higher-cost alternative to passive monitoring like a Holter monitor, which is cheaper but meant for short-term monitoring and low-risk patients. MCT is an approved procedure code that was created as a low-cost alternative when compared to in-hospital telemetry which can cost thousands of dollars per day.
Even though this type of testing is more expensive than the traditional Holter or event monitoring procedures, the cost is still a fraction of its in-hospital alternative. Our solution is unique, because while it is geared for high-risk patients and long-term monitoring, it is far cheaper and less intrusive than checking the patient into the hospital, and more effective in detecting issues than short-term monitoring.”
For a free report and the other top recommendations from the in depth interview with Waqaas Al-Siddiq, Chairman, CEO and Founder of Biotricity (OTCMKTS:BTCY), visit TWST.com.
# # #
NOTE TO INVESTORS AND FINANCIAL NEWS EDITORS: Waqaas Al-Siddiq, Chairman, CEO and Founder of Biotricity (OTCMKTS:BTCY) is available for interviews. Contact Biotricity at https://www.biotricity.com/investors/contact-investor-relations/.
– See more at https://www.twst.com/report/medical-devices-10/
